Phase 3 Hepatitis B Trial, Recruiting NCT07307586 Sponsor: Zhigang Ren Condition: Hepatitis B
Back to Hepatitis B

Phase 3 Hepatitis B Trial, Recruiting

NCT07307586
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with chronic hepatitis B according to specific Chinese medical guidelines, and who have tested positive for two hepatitis B markers (called HBeAg and HBsAg) for at least six months continuously
  • People whose hepatitis B virus levels in the blood are above a certain threshold (HBV DNA > 20,000 copies/mL) and whose HBsAg level is below a certain threshold (< 1,500 IU/mL) (confirm with trial site)
  • People whose liver enzyme levels (specifically ALT) are more than twice the upper limit of the normal range, indicating some liver inflammation
  • People who have not received any antiviral treatment before entering the study

Who may not be able to join:

  • People who are also infected with other liver-affecting viruses, such as hepatitis A, C, D, or E, or who have HIV
  • People who have other liver conditions, cirrhosis, autoimmune diseases, or other ongoing chronic health conditions
  • People who are pregnant, breastfeeding, or planning to become pregnant within one year
  • People who have received or are currently receiving cancer treatment
  • People with a history of alcohol or drug abuse
  • People who are currently taking any medications or health supplements
  • People who participated in another clinical trial within the 30 days before enrolling in this study
  • People who have a history of allergic reactions or known sensitivity to any drug or ingredient used in this study
  • People who have digestive or gastrointestinal conditions that may affect how the body absorbs medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618703636245

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Zhigang Ren
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Follow-up at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov